Lenalidomide Monotherapy in Chemotherapy-Naive, Castration-Resistant Prostate Cancer Patients: Final Results of a Phase II Study

Nabhan, Chadi; Patel, Anand; Villines, Dana; Tolzien, Kathy; Kelby, Susan K.; Lestingi, Timothy M.

doi:10.1016/j.clgc.2013.09.001

Cited by 20 publications

(15 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of 27 prostate-specific antigen evaluable patients, 13 (48%) had a decline in prostate-specific antigen level; 3 (11%) had >50% prostate-specific antigen decrease; the median time to prostate-specific antigen progression was 3 months. In this study, grade 3/4 hematologic toxicities were the most common adverse events without adverse impact on quality of life (Nabhan et al, 2014). Serious adverse events occurred in 14 patients (44%), including 1 patient (3%) with a rash definitely related to lenalidomide.…”

Section: Discussionmentioning

confidence: 99%

“…Characteristics of lenalidomide as chemotherapy, studies included in this study are presented as short-term outcomes: the response rate of Nabhan et al (2014) was 11%, of Garcia et al (2014) was 12.5%, and of Keizman et al (2010) was 18%. Totally, 98 patients were enrolled and 13 patients achieved PSA level decline of ≥50%, the pooled response rate thus was 13.3% (13/98).…”

Section: Resultsmentioning

confidence: 99%

“…Via steps of screening the title and reading the abstract, 3 studies were identified (Keizman et al, 2010;Nabhan et al, 2014;Garcia et al, 2014) when lenalidomide was used in the treatment for patients with castration-resistant prostate cancer. All these studies had been carried out in the USA.…”

Section: Resultsmentioning

confidence: 99%

“…Serious adverse events occurred in 14 patients (44%), including 1 patient (3%) with a rash definitely related to lenalidomide. Thus, they concluded that lenalidomide monotherapy was modest active in treating patients with chemotherapy-naive castration-resistant prostate cancer (Nabhan et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

“…With a purpose to assess the antitumor activity and toxicity of lenalidomide, in patients with chemotherapynaive, castration-resistant prostate cancer, Nabhan et al conducted a phase II study (Nabhan et al, 2014). They treated all patients with 25 mg/d lenalidomide for 21 days in 28-day cycles, until disease progression or unacceptable toxicity developed.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Lenalidomide in Treating Patients with Castration-Resistant Prostate Cancer

Xing

Song²,

Zhang³

2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: This analysis was conducted to evaluate the efficacy and safety of lenalidomide based regimen in treating patients with castration-resistant prostate cancer. Materials and Methods: Clinical studies evaluating the efficacy and safety of lenalidomide based regimens on response and safety for patients with castration-resistant prostate cancer were identified using a predefined search strategy. A pooled response rate (rate of PSA level decline of ≥50%) to treatment was calculated. Results: In lenalidomide based regimen, 3 clinical studies which including 98 patients with castration-resistant prostate cancer were considered eligible for inclusion. These lenalidomide based regimens included cisplatin, doxorubicin, or GM-CSF. Pooled analysis suggested that, in all patients, the pooled PSA level decline of ≥50% was 13.3% (13/98) in lenalidomide based regimens. Fatigue, nausea and vomitting were the main side effects. No grade III or IV renal or liver toxicity were observed. No treatment related death occurred in patients with lenalidomide based regimens. Conclusions: This evidence based analysis suggests that lenalidomide based regimens are associated with mild response rate and acceptable toxicities for treating patients with castration-resistant prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%